Most of the ROS-targeting drugs in development or on the market eliminate only individual types of ROS and lose function after just a single reaction. Cenyx Biotech’s cerium oxide-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback